A prospective, multicentric, phase 2 clinical trial was conducted to test a combination treatment with encorafenib (BRAFinhibitor) and binimetinib (MEK inhibitor) followed by radiotherapy in patients with BRAF V600-positive melanoma and brain metastases. This evidence concerns the gene BRAF and melanoma.